The combination of the total level of MIB2 and membrane PD-L1 or MIB2 only in NSCLC tumors is a better predictor than the level of membrane PD-L1 alone, should there be a need to select responders for anti–PD-1 (nivolumab) immunotherapy and assign nonresponders for clinical trials. The gene discussed is MIB2; the disease is non-small cell lung carcinoma.